Semaglutide / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
Wegovy, Ozempic and Rybelsus
An accessible treatment-decision site with precise product distinctions. What should I know about wegovy, ozempic and rybelsus: product and indication map?
Open the Semaglutide library ↗STEP1 randomized 1961 adults without diabetes to subcutaneous 2.4 mg semaglutide or placebo plus lifestyle support for 68 weeks.
Read the original record ↗
The original record comes first.
These are starting points for the Semaglutide library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
Keep claims and sources together.
STEP1 randomized 1961 adults without diabetes to subcutaneous 2.4 mg semaglutide or placebo plus lifestyle support for 68 weeks.
Supporting record ↗Mean weight change in STEP1 was−14.9% versus−2.4% with placebo; gastrointestinal events caused discontinuation in 4.5% versus 0.8%.
Supporting record ↗SELECT enrolled 17604 adults aged 45 or older with established cardiovascular disease and overweight/obesity but no diabetes.
Supporting record ↗SELECT major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo; hazard ratio 0.80 over mean 39.8 months follow-up.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.